|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||28.84 - 29.12|
|52 Week Range||25.55 - 35.60|
|PE Ratio (TTM)||21.78|
|Dividend & Yield||0.90 (3.11%)|
|1y Target Est||N/A|
Perrigo (PRGO) gains an FDA consent for the OTC version of AstraZeneca's Nexium post the ongoing patent lawsuit settlement through an agreement.
Eli Lilly, Incyte, and Johnson & Johnson could have the most exciting late-stage oncology candidates.
AstraZeneca PLC is betting that technology from German startup Ethris GmbH will help it add to its stockpile of treatments for respiratory diseases.